Middle East Pharmaceutical Industries Company (TADAWUL:4016)
Saudi Arabia flag Saudi Arabia · Delayed Price · Currency is SAR
131.60
0.00 (0.00%)
Mar 27, 2025, 3:14 PM AST

TADAWUL:4016 Income Statement

Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
394338.44302.66287.22301.66
Revenue Growth (YoY)
16.42%11.82%5.38%-4.79%-
Cost of Revenue
150.64131.4119.21113.47126.25
Gross Profit
243.36207.04183.45173.76175.41
Selling, General & Admin
149.95130.93113.7397.7492.87
Other Operating Expenses
-1.160.090.18-0.140.05
Operating Expenses
152.33129.51114.0497.694.92
Operating Income
91.0377.5369.4176.1680.49
Interest Expense
-4.68-5.75-4.73-1.87-1.2
Currency Exchange Gain (Loss)
--0.470.27--
Other Non Operating Income (Expenses)
----1.08-1.48
EBT Excluding Unusual Items
86.3571.3164.9573.2277.81
Gain (Loss) on Sale of Investments
----2.76-
Gain (Loss) on Sale of Assets
-0.130.08--
Pretax Income
86.3571.4465.0270.4677.81
Income Tax Expense
6.55.615.574.185
Net Income
79.8565.8359.4566.2872.81
Net Income to Common
79.8565.8359.4566.2872.81
Net Income Growth
21.30%10.72%-10.31%-8.97%-
Shares Outstanding (Basic)
2620202020
Shares Outstanding (Diluted)
2620202020
Shares Change (YoY)
28.37%----
EPS (Basic)
3.113.292.973.313.64
EPS (Diluted)
3.113.292.973.313.64
EPS Growth
-5.51%10.72%-10.31%-8.97%-
Free Cash Flow
24.1371.8258.9925.2811.42
Free Cash Flow Per Share
0.943.592.951.260.57
Gross Margin
61.77%61.18%60.61%60.50%58.15%
Operating Margin
23.11%22.91%22.93%26.52%26.68%
Profit Margin
20.27%19.45%19.64%23.08%24.14%
Free Cash Flow Margin
6.12%21.22%19.49%8.80%3.79%
EBITDA
106.8785.1476.2582.8687.19
EBITDA Margin
27.12%25.16%25.19%28.85%28.90%
D&A For EBITDA
15.847.616.846.76.69
EBIT
91.0377.5369.4176.1680.49
EBIT Margin
23.11%22.91%22.93%26.52%26.68%
Effective Tax Rate
7.53%7.85%8.57%5.93%6.43%
Updated Nov 11, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.